InvestorsHub Logo
Post# of 179891
Next 10
Followers 42
Posts 3758
Boards Moderated 0
Alias Born 08/29/2014

Re: lineItemVeto post# 82789

Friday, 09/28/2018 11:15:12 PM

Friday, September 28, 2018 11:15:12 PM

Post# of 179891
https://www.nasdaq.com/press-release/first-successful-treatment-of-canine-sarcoma-using-isopet-to-be-presented-at-veterinary-cancer-20180926-00265

I'm sorry it is at least 2 Universities (They have labs)

The IsoPet® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will continue

The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.

The Company is also engaging the FDA for clearance to market RadioGel™ for the treatment of advanced basal and squamous cell skin cancers in humans.


IsoPet® also has a short half-life - delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDGL News